ICAM1 and endometrial cancer: developed a ligand-based pharmacophore model of intercellular adhesion molecule 1 (ICAM1) inhibitors by kinetic simulation and quantum mechanics, continuously screened a variety of anticancer drugs exhibiting pharmacophore profiles that inhibit ICAM1, and combined free-energy and kinetic simulations to show that lanreotide-ICAM1 complexes, when used in the treatment of endometriosis, may delay or prevent endometrial cancer (54).